Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 113

Next Previous
Drug Profile

BNT 113

Alternative Names: BNT-113; E6/E7 RNA(LIP); HPV Anti-CD40 RNA Vaccine; HPV mRNA vaccine; RBLO 15.1(LIP)/RBLO 16.1(LIP)

Latest Information Update: 15 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I/II Cervical cancer; Penile cancer

Most Recent Events

  • 13 Sep 2024 Adverse events, immunogenicity and efficacy data from the phase I/II HARE-40 trial in Squamous cell cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 13 Sep 2024 Efficacy and adverse events data from the phase II AHEAD-MERIT trial in Squamous cell cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 24 Jan 2024 University of Southampton and Biontech completes the pgase I/II HARE-40 trial in Cervical cancer, Penile cancer and Squamous cell cancer (Second-line therapy or greater, Recurrent) in United Kingdom (Intradermal) (NCT03418480)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top